Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 8.5M | 6% |
| Gross Profit | -4M | 62% |
| Cost of Revenue | 13M | 32.6% |
| Operating expense | 29M | 25.4% |
| Net Income | -24M | 32.4% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 64M | 26.9% |
| Total Liabilities | 130M | 3% |
| Shares Outstanding | 55M | 0.4% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -19M | 36.9% |
| Cash from investing | -1.1M | 112.4% |
| Cash from financing | -1.9M | 89.1% |
EPS
Financial Highlights for Marinus Pharmaceuticals in Q3 '24
Marinus Pharmaceuticals reported a revenue of 8.5M, which is a 6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -4M, marking a 62% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 13M, a -32.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 29M, showing a -25.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -24M, showing a 32.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Marinus Pharmaceuticals with growth in revenue, gross profit, and net income.
